The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer

The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is rec...

Full description

Saved in:

Bibliographic Details
Main Author:	K. E. Borisov
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Опухоли женской репродуктивной системы
Subjects:	ovarian cancer recurrence platinum-free interval topotecan weekly regimen
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/88
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
by: E. G. Novikova, et al.
Published: (2014-07-01)

The role of topotecan in cancer ginecology treatment
by: A. G. Kedrova, et al.
Published: (2017-02-01)

Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life
by: E. G. Novikova, et al.
Published: (2014-08-01)

Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
by: Tamaki Tanaka, et al.
Published: (2025-06-01)

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
by: I. A. Pokataev, et al.
Published: (2015-11-01)

Deep learning based on ultrasound images to predict platinum resistance in patients with epithelial ovarian cancer
by: Chang Su, et al.
Published: (2025-05-01)

The trajectory of conditional, recurrence-free, and long-term survival in a complete 10-year cohort of patients with advanced ovarian cancer
by: Nina Groes Kofoed, et al.
Published: (2025-03-01)

Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study
by: Arun D. Singh, MD, et al.
Published: (2025-11-01)

Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols
by: Sattar Saima, et al.
Published: (2019-03-01)

Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
by: Bhatt Aditi, et al.
Published: (2024-07-01)

Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis
by: İrem Öner, et al.
Published: (2025-06-01)

Experience of using chemotherapy treatment for the first recurrence of ovarian cancer
by: V. N. Zhurman
Published: (2025-01-01)

THE VALUE OF CYTOREDUCTIVE SURGERY FOR ISOLATED LYMPH NODE RECURRENCE OF OVARIAN CANCER
by: H. I. Mamajonov, et al.
Published: (2020-07-01)

Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report
by: Davien Deraedt, et al.
Published: (2024-10-01)

Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data
by: Li-Rong Yang, et al.
Published: (2024-11-01)

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer
by: TIAN Yanan, ZHENG Hui, YAN Tianqing, ZHANG Heng, LU Renquan, GUO Lin
Published: (2025-04-01)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
by: Nicholas Cardillo, et al.
Published: (2022-10-01)

The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors
by: Baoyue Pan, et al.
Published: (2025-08-01)

Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study
by: Alexandra R. Steck, et al.
Published: (2025-08-01)

The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer
by: Radu-Dumitru Dragomir, et al.
Published: (2025-03-01)

Comparative effectiveness and safety of treatment regimens for recurrent advanced ovarian cancer: a systematic review and network meta-analysis
by: Xingfa Huo, et al.
Published: (2025-04-01)

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
by: İlker Selçuk, et al.
Published: (2015-04-01)

HELQ upregulates PARP1 to drive platinum resistance and predict therapeutic response in ovarian cancer
by: Shuran Tan, et al.
Published: (2025-07-01)

Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion
by: Jiong Ma, et al.
Published: (2024-12-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response
by: Guanlin Dai, et al.
Published: (2025-08-01)

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity
by: Rachel M. Hurley, et al.
Published: (2025-06-01)

Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
by: Luxitaa Goenka, et al.
Published: (2024-10-01)

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01)

Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
by: Wang Caixia, et al.
Published: (2025-01-01)

The expression of immunohistochemical biomarkers PAX8 and CD117 in platinum resistant ovarian cancer at Saiful Anwar General Hospital, Malang, Indonesia
by: Robby Rinaldi Widodo, et al.
Published: (2025-04-01)

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
by: Alessandra Dall'Acqua, et al.
Published: (2017-08-01)

Tumor Small Extracellular Vesicle‐Transmitted LncRNA CATED Promotes Platinum‐Resistance in High‐Grade Serous Ovarian Cancer
by: Yi Liu, et al.
Published: (2025-08-01)

CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study
by: Mengge He, et al.
Published: (2025-07-01)

Immunohistochemical parameters of serous ovarian carcinomas and possible mechanism of development of resistance to platinum-based drugs
by: G. V. Zhukova, et al.
Published: (2024-09-01)

Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer
by: E. M. Frantsiyants, et al.
Published: (2022-01-01)

Immunotherapy in Recurrent Ovarian Cancer
by: Keyao Chen, et al.
Published: (2025-01-01)

The Quantitative Indices of ERCC1 Expression in Serous Ovarian Cancer Tissue and the Efficacy of First-Line Platinum-Based Chemotherapy
by: T. A. Bogush, et al.
Published: (2020-05-01)

Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer
by: Xingyu Jiang, et al.
Published: (2024-12-01)

Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients
by: Al Obeed Allah Mohammad, et al.
Published: (2025-12-01)